Tamoxifen decreases ovarian toxicity without compromising cancer treatment in a rat model of mammary cancer

他莫昔芬可降低乳腺癌大鼠模型的卵巢毒性,且不会影响癌症治疗

阅读:12
作者:Anna Nynca, Sylwia Swigonska, Monika Ruszkowska, Agnieszka Sadowska, Karina Orlowska, Tomasz Molcan, Kamil Myszczynski, Iwona Otrocka-Domagala, Katarzyna Paździor-Czapula, Beata Kurowicka, Brian Kelli Petroff, Renata Elzbieta Ciereszko

Background

Premenopausal women diagnosed with breast cancer often face aggressive chemotherapy resulting in infertility. Tamoxifen (TAM) is a selective estrogen receptor modulator that was previously suggested as a protective agent against chemotherapy-induced ovarian failure. In the current study, we examined mechanisms of the protective action of TAM in the ovaries of tumor-bearing rats treated with the chemotherapy drug cyclophosphamide (CPA).

Conclusions

Tamoxifen shielded the ovary from the side effects of chemotherapy without lessening the tumoricidal actions of mammary cancer treatment.

Results

TAM prevented CPA-induced loss of ovarian follicular reserves. The protective TAM effect in the rat ovary partially resulted from decreased apoptosis. In addition, transcriptomic and proteomic screening also implicated the importance of DNA repair pathways as well as cell adhesion and extracellular matrix remodeling in the protective ovarian actions of TAM. Conclusions: Tamoxifen shielded the ovary from the side effects of chemotherapy without lessening the tumoricidal actions of mammary cancer treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。